Workflow
细胞+基因精准医疗
icon
Search documents
宁美浩维完成数千万天使轮融资
Sou Hu Cai Jing· 2025-05-12 00:21
Core Viewpoint - Beijing Ningmeihao Wei Biotechnology Co., Ltd. has completed tens of millions in angel round financing to support research and industrialization in gene-edited cell therapy, focusing on clinical applications in precision anti-aging and chronic disease treatment [1][4] Group 1: Company Overview - Ningmeihao Wei was founded in 2015 and aims to provide comprehensive precision medical and health management solutions throughout the disease prevention, diagnosis, and treatment lifecycle [1][5] - The founding team consists of top domestic and international experts in life sciences and clinical medicine, with over a decade of experience in cell research and gene therapy [1] Group 2: Business Focus - The company focuses on a "cell + gene" dual-core strategy to build a precision medical ecosystem covering the entire lifecycle, including personalized anti-aging solutions and chronic disease treatments [1][2] - In chronic disease treatment, Ningmeihao Wei is advancing stem cell therapy applications for diabetes, cardiovascular diseases, and neurological disorders, collaborating with clinical institutions for efficacy evaluation [1][3] Group 3: Technology and Innovation - The company utilizes advanced technologies for stem cell preparation and NK cell production, adhering to pharmaceutical-grade cell production systems and quality management standards to ensure safety and efficacy [3][4] - Ningmeihao Wei has developed a dual technology platform of "pluripotent stem cell directed differentiation + gene editing" to explore treatment solutions for diabetes by repairing damaged pancreatic cells and restoring insulin secretion [3] Group 4: Quality Control and Future Plans - The company has a stringent quality control system ensuring low immunogenicity and safety of cell sources, with cells stored in top-tier facilities for long-term use [4] - Future development plans include expanding the application of stem cell therapy in precision anti-aging and chronic disease treatment, driving the industrialization of cell therapy technologies [4][5]